Ann‐Lii Cheng

Researcher Next ID · RN-014264

Researcher · Medicine

, Taiwan

Not currently recruitingFunding unknown

Research interests

Medicine

Hepatocellular Carcinoma Treatment and Prognosis

Colorectal Cancer Treatments and Studies

Cancer Immunotherapy and Biomarkers

Lung Cancer Treatments and Mutations

Cancer Mechanisms and Therapy

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
New England Journal of Medicine · 2020 · 10.1056/nejmoa1915745
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
The Lancet · 2018 · 10.1016/s0140-6736(18)30207-1
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
The Lancet Oncology · 2018 · 10.1016/s1470-2045(18)30351-6
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet · 2016 · 10.1016/s0140-6736(16)32453-9
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
The Lancet Oncology · 2008 · 10.1016/s1470-2045(08)70285-7

No projects listed.